article
4 July 2023 | By Dr Jeff Mocny (Abenza), Dr Petra Dieterich (Abenza), Ian Glassford (Abenza)
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further…